Anti-IgE treatment in allergic rhinitis
- PMID: 31526939
- DOI: 10.1016/j.ijporl.2019.109674
Anti-IgE treatment in allergic rhinitis
Abstract
Objectives: To review the efficacy of anti-IgE therapy in allergic rhinitis (AR).
Methods: Literature search was performed using the PubMed and Proquest Central databases at Kırıkkale University Library.
Results: Although the skin prick testing in patients suffering from AR is positive (indicating that antigen-specific Immunoglobulin E has been produced), there is no association with overall circulating IgE levels. Correlation was lacking between circulating IgE level and either skin prick tests or laboratory testing for specific IgE. Omalizumab binds to uncomplexed IgE in man more avidly than does Fc-epsilon. The effect of omalizumab is to lower the level of IgE and downgrade production of FceRI receptors (which bind IgE) in mast cells and basophils, causing less mast cell recruitment and responsivity and thus diminishing eosinophilic infiltration and activation. Anti-IgE therapy through omalizumab may shorten the lifetime of mast cells and causes dendritic cells to downgrade their production of FcεRI. There are reports indicating benefit from omalizumab in managing food allergies, nasal polyp formation, essential anaphylaxis, AR, venom allergy and eczema. Omalizumab acts to lessen circulating IgE levels, whilst reducing production of FceRI by mast cells and basophils. The fact that omalizumab influences how eosinophils respond may be down to disruption of the antigen-IgE-mast cell interactions, with mast cells being recruited at lower levels and thus chemotactic eosinophilic recruitment via cytokines being greatly reduced. Omalizumab has the effect in cases of perennial AR of blocking the increased eosinophilic recruitment and tissue infiltration initiated by seasonal antigens. Likewise, in omalizumab-treated cases, circulating unbound IgE levels showed significant decreases. For patients with perennial AR, the average daily nasal severity score was significantly reduced where omalizumab was administered, compared to placebo.
Conclusion: Omalizumab has efficacy in ameliorating symptoms and reduces the necessity for additional medication in both seasonal and perennial allergic rhinitis.
Keywords: Allergic rhinitis; Anti-IgE treatment; Omalizumab; Perennial allergic rhinitis; Seasonal allergic rhinitis.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Etiopathogenesis and management of perennial allergic rhinitis: a state-of-the-art review.Treat Respir Med. 2004;3(1):45-57. doi: 10.2165/00151829-200403010-00006. Treat Respir Med. 2004. PMID: 15174893 Review.
-
Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.Clin Exp Allergy. 2005 Apr;35(4):408-16. doi: 10.1111/j.1365-2222.2005.02191.x. Clin Exp Allergy. 2005. PMID: 15836747 Review.
-
Anti-IgE for the treatment of allergic rhinitis--and eventually nasal polyps?Int Arch Allergy Immunol. 2009;148(2):87-98. doi: 10.1159/000155739. Epub 2008 Sep 18. Int Arch Allergy Immunol. 2009. PMID: 18799888 Review.
-
Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.JAMA. 2001 Dec 19;286(23):2956-67. doi: 10.1001/jama.286.23.2956. JAMA. 2001. PMID: 11743836 Clinical Trial.
-
The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.J Allergy Clin Immunol. 2005 Mar;115(3):459-65. doi: 10.1016/j.jaci.2004.11.053. J Allergy Clin Immunol. 2005. PMID: 15753888 Review.
Cited by
-
RORα overexpression reduced interleukin-33 expression and prevented mast cell degranulation and inflammation by inducing autophagy in allergic rhinitis.Immun Inflamm Dis. 2023 Oct;11(10):e1017. doi: 10.1002/iid3.1017. Immun Inflamm Dis. 2023. PMID: 37904695 Free PMC article.
-
Roles of mast cells and their interactions with the trigeminal nerve in migraine headache.Mol Pain. 2023 Jan-Dec;19:17448069231181358. doi: 10.1177/17448069231181358. Mol Pain. 2023. PMID: 37232078 Free PMC article. Review.
-
Effect of immunostimulation with bacterial lysate on the clinical course of allergic rhinitis and the level of γδT, iNKT and cytotoxic T cells in children sensitized to grass pollen allergens: A randomized controlled trial.Front Immunol. 2023 Jan 17;14:1073788. doi: 10.3389/fimmu.2023.1073788. eCollection 2023. Front Immunol. 2023. PMID: 36733480 Free PMC article. Clinical Trial.
-
Therapeutic effect of Biyuan tongqiao granules combined with mometasone furoate nasal spray on clinical symptoms of children with allergic rhinitis.Am J Transl Res. 2022 Jul 15;14(7):5116-5123. eCollection 2022. Am J Transl Res. 2022. PMID: 35958511 Free PMC article.
-
Efficacy and Safety of Rupatadine Fumarate Combined with Acupoint Application in Allergic Rhinitis Complicated with Diabetes.Comput Intell Neurosci. 2022 Jun 14;2022:6935758. doi: 10.1155/2022/6935758. eCollection 2022. Comput Intell Neurosci. 2022. Retraction in: Comput Intell Neurosci. 2023 Dec 13;2023:9803914. doi: 10.1155/2023/9803914. PMID: 35747720 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials